Many of the assets came out of Chinese labs, and much of the money behind them rides on science still years from proving out.
Two would-be contenders answered the same question this week, how to stay relevant when you are not the United States, and they answered it in different currencies: one in words, one in yen.
The FTC has told a federal appeals court that what J&J did to competition matters more than what it meant to do. That, along with a big recent Takeda verdict, should change how you think about every defensive patent move.
Who, and what, gets trusted with the next decade of drug discovery. The answers, so far: an AI résumé, and in China, a shrug.
Money is everywhere and buyers are hungry, so biotechs are seeing several suitors at once and in no rush to commit. The complications: the most wanted assets keep turning up in China, and a US pricing rule means no deal abroad stays abroad.
Christophe Weber leaves a global top-ten drugmaker, and the debt it took to get there. The verdict now belongs to the executive who arrived in the very transaction that made it.
Psychedelics produce their best clinical readout yet, while chip-making juggernaut NVIDIA turns its gaming fortunes into a pharma play.
The EU’s debut Joint Clinical Assessment was run on a drug that exposes every trap waiting for orphan developers in 2028.
The convention opens with the FDA short of leaders, while Europe's new drug-vetting system stumbles on its first attempt.
A cluster of recent deals put AI discovery platforms at the center. The terms, optioned and hedged, are more cautious than the conviction suggests.
